CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The Use of a High Flow PICC Catheter for Stem Cell and Lymphocyte Apheresis: The Initial Experience of a Pediatric Oncology Center in Brazil.
The Use of a High Flow PICC Catheter for Stem Cell and Lymphocyte Apheresis: The Initial Experience of a Pediatric Oncology Center in Brazil.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
高流量 PICC 是 apheresis 的可行替代方案,可维持 5 ml/s 的充分流速,并可在整个 HSCT 过程中作为单根导管使用,从而减少麻醉和导管置入操作带来的风险。研究类型:临床研究。
自体造血干细胞移植(HSCT)以高强度化疗后输注先前从外周血采集的HSC为特征,是一种用于治疗多种恶性肿瘤的操作。在儿科中,由于需要在幼童体内置入硬质中心静脉导管(CVC),血浆置换操作是一项挑战。CVC通常用于干细胞采集,随后被拔除。之后,患者将需要新的装置用于细胞输注。
我们提出使用单根导管同时进行单采和输注。
我们报告了5名1至13岁儿童,他们使用手术置入的高流量PICC导管进行了单采术。
所有患者均使用5Fr双腔PICC导管(PowerPICC 5Fr DL BARD/USA),置于头臂静脉并经胸壁隧道化,在单采前24小时内插入以确保装置通畅。其中三名患者诊断为实体瘤,一名诊断为急性淋巴细胞白血病(ALL),等待CAR-T 细胞治疗。四名接受自体HSCT的儿童使用同一导管进行细胞输注,并在出院后保留导管。那名准备接受CAR-T 细胞治疗的孩子仍在等待输注,导管已拔除。
Autologous hematopoietic stem cell transplant (HSCT), characterized by high intensity chemotherapy followed by the infusion of HSC previously collected from the peripheral blood, is a procedure used in the treatment of several malignancies. In pediatrics, the apheresis procedure represents a challenge, due to the need for insertion of a rigid central venous catheter (CVC) in small children. The CVC is usually used for stem cell collection and then removed. Later, the patient will need a new device for cell infusion. AIM: We propose the use of one single catheter for both apheresis and infusion.
We present five children between 1 and 13 years of age who underwent apheresis using a high flow PICC catheter surgically inserted.
All patients utilized a PICC line double lumen 5Fr (PowerPICC 5Fr DL BARD/USA) placed in the brachiocephalic vein tunneled on the chest, inserted under 24 h prior to apheresis to assure the devices were pervious. Three of the patients were diagnosed with solid tumor and one with acute lymphoblastic leukemia (ALL) awaiting Car-T Cell therapy. The four children who underwent autologous HSCT used the same catheter for cell infusion and remained with the catheter following discharge. The child who was submitted for Car-T Cell still awaits infusion and the catheter was removed.
High flow PICC is a viable alternative for apheresis to maintain an adequate flow of 5 ml/s and can be used as a single catheter throughout the HSCT process, reducing the risks from anesthesia and the catheter insertion procedure. TYPE OF STUDY: Clinical Research.
MEMBER ACCOUNT
登录成功会直接打开下一页。